Hematology

January 27, 2023

Pirtobrutinib has been approved for patients with mantle cell lymphoma. The prescribing label comes with warnings for infections, hemorrhage, cytopenias, atrial fibrillation and flutter, second primary malignancies, and embryo-fetal toxicity.

January 26, 2023

Investigators identified underrepresentation and imbalances in demographic and geographic representation in clinical trials leading to FDA approvals.

January 19, 2023

The FDA has approved zanubrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The prescribing label comes with warnings for hemorrhage, infections, cytopenias, second primary malignancies, and cardiac arrythmias.

January 17, 2023

Moxetumomab pasudotox-tdfk, a treatment for patients with relapsed/refractory hairy cell leukemia, will be permanently discontinued.

January 17, 2023

Among 17 patients with mantle cell lymphoma, the complete remission rate with first-line treatment with zanubrutinib plus rituximab followed by short-course rituximab plus dexamethasone, high-dose cytarabine, and oxaliplatin was 88.2%.

January 13, 2023

Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP, discusses key data of interest from the 2022 American Society of Hematology Meeting.

January 12, 2023

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, highlights her top takeaways from the 64th American Society of Hematology Annual Meeting and Exposition.

January 12, 2023

Adding induction to standard chemoimmunotherapy followed by autologous stem cell transplantation and maintenance ibrutinib was highly effective in patients with mantle cell lymphoma.

January 11, 2023

Zanubrutinib demonstrated a superior reduction in the risk of progression or death for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma compared with ibrutinib.

January 05, 2023

An economic analysis showed that neither polatuzumab vedotin nor CD19-directed CAR T-cell therapy are likely to be the most cost-effective for patients with diffuse large B-cell lymphoma based on their high costs and current long-term survival estimates.